MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2024.114028

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2024

Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.

Ruf Theresa, Kramer Rafaela, Forschner Andrea, Leiter Ulrike, Meier Friedegund, Reinhardt Lydia, Dücker Pia, Ertl Carolin, Tomsitz Dirk, Tietze Julia K, Gutzmer Ralf, Dabrowski Evelyn, Zimmer Lisa, Gesierich Anja, Zierold Sarah, French Lars E, Eigentler Thomas, Amaral Teresa, Heinzerling Lucie

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Immune checkpoint inhibitors (ICI) induce adverse events (irAEs) that do not respond to steroids, i.e. steroid-refractory (sr) irAEs, and irAEs in which steroids cannot be tapered, i.e. steroid-dependent (sd) irAEs, in about 10% of cases. An evidence-based analysis of the effectiveness of second-line immunosuppressive agents with regard to irAE and tumor control is lacking.

METHODS

The international web-based Side Effect Registry Immuno-Oncology (SERIO; http://serio-registry.org) is a collaborative initiative with the Paul-Ehrlich-Institute to document rare, severe, complex or therapy-refractory immunotherapy-induced side effects. The registry was queried on August 1, 2023 for cases of irAEs which were treated with second-line therapies.

RESULTS

From a total of 1330 cases, 217 patients (16.3%) received 249 second-line therapies. A total of 19 different second-line therapies were employed, including TNF-alpha antagonists (46.5%), intravenous immunoglobulins (IVIG; 19.1%), mycophenolate mofetil (15.9%), and methotrexate (3.6%). Therapy choices were determined by the type of irAE. The time to onset of sr-/sd-irAEs after ICI initiation did not consistently differ from steroid-responsive irAEs. While 74.3% of sr-/sd-irAEs resolved and 13.1% had improved, 4.3% persisted, 3.9% resulted in permanent sequelae, and 4.3% in death with ongoing symptoms. Infliximab exhibited potential for earlier symptom improvement compared to mycophenolate mofetil or IVIG. Tumor response in patients with second-line treated sd-/sr-irAE was similar to patients with irAEs treated with steroids only.

CONCLUSION

Several second-line therapies are effective against sr-/sd-irAEs, the second-line therapies show no clear negative impact on tumor response, and infliximab shows potential for faster improvement of symptoms. However, prospective comparative data are needed.

Для цитирования: Ruf Theresa, Kramer Rafaela, Forschner Andrea, Leiter Ulrike, Meier Friedegund, Reinhardt Lydia, Dücker Pia, Ertl Carolin, Tomsitz Dirk, Tietze Julia K, Gutzmer Ralf, Dabrowski Evelyn, Zimmer Lisa, Gesierich Anja, Zierold Sarah, French Lars E, Eigentler Thomas, Amaral Teresa, Heinzerling Lucie. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.. European journal of cancer (Oxford, England : 1990). 2024. DOI: 10.1016/j.ejca.2024.114028.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.